Literature DB >> 6289778

Immune response to a DNA free herpes simplex vaccine in man.

R Cappel, S Sprecher, F Rickaert, F de Cuyper.   

Abstract

A DNA-free subunit herpes simplex virus (HSV) vaccine was administered to 15 volunteers without past evidence of HSV infection and to 25 patients with severe recurrent HSV infection. The immune response to the vaccine in these patients was compared to the immunological status of 20 non-vaccinated control patients with recurrent HSV infection. The vaccine elicited antibody and cell-mediated immunity (CMI) in the 15 subjects without past evidence of HSV infection and this response was similar to that observed after a natural infection. Among the 25 patients who were suffering from recurrent HSV infection the vaccine elicited complement dependent cytotoxic antibodies in 13 of these patients who did not possess these antibodies and increased significantly the titers of these antibodies in the 12 other patients. The vaccine gave a significant increase of the titers of the other specific antibodies as well as the level of cell-mediated immunity. The increase of the immunity level in these latter patient was not due to normal variations since in the non-vaccinated control group the antibody titers and CMI remained stable during the same period of time.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289778     DOI: 10.1007/bf01341728

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  10 in total

1.  Herpes simplex virus vaccines.

Authors:  T G Wise; P R Pavan; F A Ennis
Journal:  J Infect Dis       Date:  1977-11       Impact factor: 5.226

2.  Antibody and cell-mediated immunity to a DNA free herpes simplex subunit vaccine.

Authors:  R Cappel; F de Cuyper; J de Braekeleer
Journal:  Dev Biol Stand       Date:  1979

3.  Comparison of the humoral and cellular immune response after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations.

Authors:  R Cappel
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

4.  Letter: Viral-antibody detection by a more sensitive complement-fixation reaction.

Authors:  G Zissis; G Clinet
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

5.  Contactual lysis of antibody-coated chicken erythrocytes by purified lymphocytes.

Authors:  P Perlmann; H Perlmann
Journal:  Cell Immunol       Date:  1970-09       Impact factor: 4.868

6.  Efficacy of a nucleic acid free herpetic subunit vaccine.

Authors:  R Cappel; F de Cuyper; F Rickaert
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

7.  Herpes simplex vaccines.

Authors:  M R Hilleman
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

8.  Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.

Authors:  E N Kitces; P S Morahan; J G Tew; B K Murray
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

9.  Herpesvirus type 2: association with carcinoma of the cervix.

Authors:  W E Rawls; W A Tompkins; M E Figueroa; J L Melnick
Journal:  Science       Date:  1968-09-20       Impact factor: 47.728

10.  Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.

Authors:  R J Klein; E Buimovici-Klein; H Moser; R Moucha; J Hilfenhaus
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

  10 in total
  9 in total

Review 1.  Control of STDs--the role of prophylactic vaccines against herpes simplex virus.

Authors:  L R Stanberry
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

2.  Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.

Authors:  G R Skinner; C Fink; J Melling; C Wiblin; B Thornton; J Hallworth; W Gardner; P McLeish; C Hartley; A Buchan
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

3.  Antibody reactivity with Skinner HSV vaccine.

Authors:  E M Muniu; J Durham; D Shariff; C E Hartley; A Fuller; J Melling; C Wiblin; G Wilkins; A Buchan; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

4.  Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine.

Authors:  G R Skinner; C G Fink; M Cowan; A Buchan; A Fuller; C E Hartley; J Durham; C Wiblin; J Melling
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

5.  Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2.

Authors:  D Long; T J Madara; M Ponce de Leon; G H Cohen; P C Montgomery; R J Eisenberg
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

6.  Viral vaccines: the use of currently available products and future developments.

Authors:  E Norrby
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

7.  Immunogenicity of purified glycoprotein gB of herpes simplex virus.

Authors:  Y Kino; T Eto; K Nishiyama; N Ohtomo; R Mori
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

8.  Effect of thymopentin on the mortality and immune response after an experimental herpes simplex infection in mice.

Authors:  R Cappel; F de Cuyper; K De Neef; W Höbel; K Bolla
Journal:  Surv Immunol Res       Date:  1985

9.  In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model.

Authors:  J I Sin; J J Kim; J D Boyer; R B Ciccarelli; T J Higgins; D B Weiner
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.